383 related articles for article (PubMed ID: 21716073)
1. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults.
Min S; Sloan L; DeJesus E; Hawkins T; McCurdy L; Song I; Stroder R; Chen S; Underwood M; Fujiwara T; Piscitelli S; Lalezari J
AIDS; 2011 Sep; 25(14):1737-45. PubMed ID: 21716073
[TBL] [Abstract][Full Text] [Related]
2. Dolutegravir versus placebo in subjects harbouring HIV-1 with integrase inhibitor resistance associated substitutions: 48-week results from VIKING-4, a randomized study.
Akil B; Blick G; Hagins DP; Ramgopal MN; Richmond GJ; Samuel RM; Givens N; Vavro C; Song IH; Wynne B; Ait-Khaled M;
Antivir Ther; 2015; 20(3):343-8. PubMed ID: 25321146
[TBL] [Abstract][Full Text] [Related]
3. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.
Cahn P; Pozniak AL; Mingrone H; Shuldyakov A; Brites C; Andrade-Villanueva JF; Richmond G; Buendia CB; Fourie J; Ramgopal M; Hagins D; Felizarta F; Madruga J; Reuter T; Newman T; Small CB; Lombaard J; Grinsztejn B; Dorey D; Underwood M; Griffith S; Min S;
Lancet; 2013 Aug; 382(9893):700-8. PubMed ID: 23830355
[TBL] [Abstract][Full Text] [Related]
4. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.
Raffi F; Rachlis A; Stellbrink HJ; Hardy WD; Torti C; Orkin C; Bloch M; Podzamczer D; Pokrovsky V; Pulido F; Almond S; Margolis D; Brennan C; Min S;
Lancet; 2013 Mar; 381(9868):735-43. PubMed ID: 23306000
[TBL] [Abstract][Full Text] [Related]
5. Short-term antiviral activity of TMC278--a novel NNRTI--in treatment-naive HIV-1-infected subjects.
Goebel F; Yakovlev A; Pozniak AL; Vinogradova E; Boogaerts G; Hoetelmans R; de Béthune MP; Peeters M; Woodfall B
AIDS; 2006 Aug; 20(13):1721-6. PubMed ID: 16931936
[TBL] [Abstract][Full Text] [Related]
6. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults.
Schürmann D; Fätkenheuer G; Reynes J; Michelet C; Raffi F; van Lier J; Caceres M; Keung A; Sansone-Parsons A; Dunkle LM; Hoffmann C
AIDS; 2007 Jun; 21(10):1293-9. PubMed ID: 17545705
[TBL] [Abstract][Full Text] [Related]
7. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.
van Lunzen J; Maggiolo F; Arribas JR; Rakhmanova A; Yeni P; Young B; Rockstroh JK; Almond S; Song I; Brothers C; Min S
Lancet Infect Dis; 2012 Feb; 12(2):111-8. PubMed ID: 22018760
[TBL] [Abstract][Full Text] [Related]
8. Dolutegravir: clinical and laboratory safety in integrase inhibitor-naive patients.
Curtis L; Nichols G; Stainsby C; Lim J; Aylott A; Wynne B; Clark A; Bloch M; Maechler G; Martin-Carpenter L; Raffi F; Min S
HIV Clin Trials; 2014; 15(5):199-208. PubMed ID: 25350958
[TBL] [Abstract][Full Text] [Related]
9. Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program.
Descamps D; Peytavin G; Visseaux B; Tubiana R; Damond F; Campa P; Charpentier C; Khuong-Josses MA; Duvivier C; Karmochkine M; Lukiana T; Matheron S
Clin Infect Dis; 2015 May; 60(10):1521-7. PubMed ID: 25690598
[TBL] [Abstract][Full Text] [Related]
10. ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects.
Letendre SL; Mills AM; Tashima KT; Thomas DA; Min SS; Chen S; Song IH; Piscitelli SC;
Clin Infect Dis; 2014 Oct; 59(7):1032-7. PubMed ID: 24944232
[TBL] [Abstract][Full Text] [Related]
11. Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study.
Stellbrink HJ; Reynes J; Lazzarin A; Voronin E; Pulido F; Felizarta F; Almond S; St Clair M; Flack N; Min S;
AIDS; 2013 Jul; 27(11):1771-8. PubMed ID: 23807273
[TBL] [Abstract][Full Text] [Related]
12. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
Santevecchi BA; Miller S; Childs-Kean LM
Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
[TBL] [Abstract][Full Text] [Related]
13. Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals.
Markowitz M; Morales-Ramirez JO; Nguyen BY; Kovacs CM; Steigbigel RT; Cooper DA; Liporace R; Schwartz R; Isaacs R; Gilde LR; Wenning L; Zhao J; Teppler H
J Acquir Immune Defic Syndr; 2006 Dec; 43(5):509-15. PubMed ID: 17133211
[TBL] [Abstract][Full Text] [Related]
14. A dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience.
Schooley RT; Clumeck N; Haubrich R; Thompson M; Danner SA; van Der Ende ME; Sereni D; Antunes F; Blake D; Myers RE; Tisdale M; Millard J; Mustafa N; Nacci P
Antivir Ther; 2001 Jun; 6(2):89-96. PubMed ID: 11491421
[TBL] [Abstract][Full Text] [Related]
15. Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis.
Snedecor SJ; Radford M; Kratochvil D; Grove R; Punekar YS
BMC Infect Dis; 2019 May; 19(1):484. PubMed ID: 31146698
[TBL] [Abstract][Full Text] [Related]
16. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
[TBL] [Abstract][Full Text] [Related]
17. Randomized placebo-controlled study of the safety, tolerability, antiviral activity, and pharmacokinetics of 10-day monotherapy with BMS-986001, a novel HIV NRTI, in treatment-experienced HIV-1-infected subjects.
Cotte L; Dellamonica P; Raffi F; Yazdanpanah Y; Molina JM; Boué F; Urata Y; Chan HP; Zhu L; Chang I; Bertz R; Hanna GJ; Grasela DM; Hwang C
J Acquir Immune Defic Syndr; 2013 Jul; 63(3):346-54. PubMed ID: 23771104
[TBL] [Abstract][Full Text] [Related]
18. Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study.
Castagna A; Maggiolo F; Penco G; Wright D; Mills A; Grossberg R; Molina JM; Chas J; Durant J; Moreno S; Doroana M; Ait-Khaled M; Huang J; Min S; Song I; Vavro C; Nichols G; Yeo JM;
J Infect Dis; 2014 Aug; 210(3):354-62. PubMed ID: 24446523
[TBL] [Abstract][Full Text] [Related]
19. Early clinical experience of dolutegravir in an HIV cohort in a larger teaching hospital.
Todd S; Rafferty P; Walker E; Hunter M; Dinsmore WW; Donnelly CM; McCarty EJ; Quah SP; Emerson CR
Int J STD AIDS; 2017 Oct; 28(11):1074-1081. PubMed ID: 28118801
[TBL] [Abstract][Full Text] [Related]
20. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV.
Shah BM; Schafer JJ; Desimone JA
Pharmacotherapy; 2014 May; 34(5):506-20. PubMed ID: 24347095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
